Works matching IS 17762596 AND DT 2024 AND VI 19 AND IP 1
Results: 14
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 41, doi. 10.1007/s11523-023-01022-z
- By:
- Publication type:
- Article
Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 81, doi. 10.1007/s11523-023-01030-z
- By:
- Publication type:
- Article
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 29, doi. 10.1007/s11523-023-01029-6
- By:
- Publication type:
- Article
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 115, doi. 10.1007/s11523-023-01026-9
- By:
- Publication type:
- Article
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Pemigatinib: A Review in Advanced Cholangiocarcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 107, doi. 10.1007/s11523-023-01024-x
- By:
- Publication type:
- Article
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 51, doi. 10.1007/s11523-023-01028-7
- By:
- Publication type:
- Article
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 59, doi. 10.1007/s11523-023-01027-8
- By:
- Publication type:
- Article
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8<sup>+</sup> Lymphocyte Repopulation in Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 95, doi. 10.1007/s11523-023-01019-8
- By:
- Publication type:
- Article
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 71, doi. 10.1007/s11523-023-01018-9
- By:
- Publication type:
- Article
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 13, doi. 10.1007/s11523-023-01017-w
- By:
- Publication type:
- Article
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 1, doi. 10.1007/s11523-023-01016-x
- By:
- Publication type:
- Article